Klaus Kallenbach

1.6k total citations
19 papers, 368 citations indexed

About

Klaus Kallenbach is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Klaus Kallenbach has authored 19 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Klaus Kallenbach's work include Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (6 papers) and Diabetes Management and Research (3 papers). Klaus Kallenbach is often cited by papers focused on Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (6 papers) and Diabetes Management and Research (3 papers). Klaus Kallenbach collaborates with scholars based in Denmark, United States and Germany. Klaus Kallenbach's co-authors include Malakh Shrestha, Sven Peterß, Jette Lautrup Frederiksen, Ludwig Hoy, Christian Hagl, Axel Haverich, Michael Winterhalter, Hiroyuki Kamiya, Nawid Khaladj and Henrik Larsson and has published in prestigious journals such as PLoS ONE, Neurology and Diabetes.

In The Last Decade

Klaus Kallenbach

18 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Klaus Kallenbach Denmark 9 154 106 79 74 69 19 368
Anri Inaki Japan 13 80 0.5× 88 0.8× 102 1.3× 70 0.9× 179 2.6× 67 551
Peeter Kööbi Finland 15 68 0.4× 72 0.7× 56 0.7× 109 1.5× 75 1.1× 28 498
Nur Kebapçı Türkiye 12 53 0.3× 69 0.7× 204 2.6× 57 0.8× 141 2.0× 36 563
Mao-Shin Lin Taiwan 13 203 1.3× 135 1.3× 70 0.9× 170 2.3× 62 0.9× 21 568
Valerie I. Elmalem United States 7 29 0.2× 46 0.4× 89 1.1× 62 0.8× 205 3.0× 12 402
Michelle Roytman United States 13 83 0.5× 36 0.3× 68 0.9× 60 0.8× 114 1.7× 41 545
Steve Orme United Kingdom 13 49 0.3× 87 0.8× 267 3.4× 75 1.0× 125 1.8× 29 517
Yi-Wen Chen Taiwan 11 70 0.5× 30 0.3× 24 0.3× 44 0.6× 122 1.8× 20 305
Anna Evangelista Italy 11 67 0.4× 294 2.8× 74 0.9× 139 1.9× 30 0.4× 16 492
M Houde Canada 9 46 0.3× 167 1.6× 64 0.8× 51 0.7× 62 0.9× 22 362

Countries citing papers authored by Klaus Kallenbach

Since Specialization
Citations

This map shows the geographic impact of Klaus Kallenbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Kallenbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Kallenbach more than expected).

Fields of papers citing papers by Klaus Kallenbach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Kallenbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Kallenbach. The network helps show where Klaus Kallenbach may publish in the future.

Co-authorship network of co-authors of Klaus Kallenbach

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Kallenbach. A scholar is included among the top collaborators of Klaus Kallenbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Kallenbach. Klaus Kallenbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Kushner, Robert F., Donna H. Ryan, John Deanfield, et al.. (2025). Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity. 33(3). 452–462. 7 indexed citations
2.
Aroda, Vanita R., Robert Bauer, Erik Christiansen, et al.. (2022). Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes Obesity and Metabolism. 24(7). 1338–1350. 27 indexed citations
3.
4.
5.
Kristensen, Helene Bjørg, Thomas Levin Andersen, Andrea Patriarca, et al.. (2021). Human hematopoietic microenvironments. PLoS ONE. 16(4). e0250081–e0250081. 7 indexed citations
6.
Goldenberg, Ronald, et al.. (2021). Achievement of Near-Normal HbA1c With Early Initiation of Oral Semaglutide: An Exploratory Subgroup Analysis of PIONEER 1. Canadian Journal of Diabetes. 45(7). S28–S29.
7.
Desouza, Cyrus, Aslam Amod, Klaus Kallenbach, et al.. (2020). 930-P: Efficacy of Oral Semaglutide According to Race: An Exploratory Subgroup Analysis of the PIONEER Trial Program. Diabetes. 69(Supplement_1). 4 indexed citations
8.
Rytlewski, Julie, James S. Wilmott, Martín C. Mihm, et al.. (2020). Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. Nature Cancer. 1(2). 197–209. 19 indexed citations
9.
Hunt, Barnaby, Brian Bekker Hansen, Åsa Ericsson, et al.. (2019). Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States. Advances in Therapy. 36(12). 3483–3493. 18 indexed citations
10.
Luehr, Maximilian, Sven Peterß, Andreas Zierer, et al.. (2017). Aortic events and reoperations after elective arch surgery: incidence, surgical strategies and outcomes†. European Journal of Cardio-Thoracic Surgery. 53(3). 519–524. 15 indexed citations
11.
Holmström, Morten Orebo, Klaus Kallenbach, Lasse Kjær, et al.. (2015). Nye sygdomsmarkører ved de kroniske myeloproliferative neoplasier. Ugeskrift for Læger. 177(26). 2–6. 2 indexed citations
12.
Holmström, Morten Orebo, Klaus Kallenbach, Lasse Kjær, et al.. (2015). [New disease markers within the chronic myeloproliferative neoplasms].. PubMed. 177(19). 1 indexed citations
13.
Kallenbach, Klaus. (2014). Bewertung der medizinischen Forschungsleistung. Zeitschrift für Herz- Thorax- und Gefäßchirurgie. 28(6). 393–394. 1 indexed citations
14.
Kodolitsch, Yskert Von, A. Bernhardt, Christian Detter, et al.. (2013). Strategisches Denken als Schlüssel zu chirurgischer Exzellenz. Zeitschrift für Herz- Thorax- und Gefäßchirurgie. 27(4). 282–289. 3 indexed citations
15.
Kallenbach, Klaus, et al.. (2011). Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Multiple Sclerosis Journal. 18(1). 72–81. 44 indexed citations
16.
Kallenbach, Klaus, Helle Juhl Simonsen, B. Sander, et al.. (2010). Retinal nerve fiber layer thickness is associated with lesion length in acute optic neuritis. Neurology. 74(3). 252–258. 23 indexed citations
17.
Khaladj, Nawid, Malakh Shrestha, Sven Peterß, et al.. (2008). Hypothermic circulatory arrest with selective antegrade cerebral perfusion in ascending aortic and aortic arch surgery: A risk factor analysis for adverse outcome in 501 patients. Journal of Thoracic and Cardiovascular Surgery. 135(4). 908–914. 151 indexed citations
18.
Kallenbach, Klaus & Jette Lautrup Frederiksen. (2007). Unilateral optic neuritis as the presenting symptom of human immunodeficiency virus toxoplasmosis infection*. Acta Ophthalmologica. 86(4). 459–460. 8 indexed citations
19.
Kallenbach, Klaus, Harold Fernandez, Graziano Seghezzi, et al.. (2003). A Quantitative In Vitro Model of Smooth Muscle Cell Migration Through the Arterial Wall Using the Human Amniotic Membrane. Arteriosclerosis Thrombosis and Vascular Biology. 23(6). 1008–1013. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anri Inaki Breakdown of academic impact, for papers by Peeter Kööbi Breakdown of academic impact, for papers by Nur Kebapçı Breakdown of academic impact, for papers by Mao-Shin Lin Breakdown of academic impact, for papers by Valerie I. Elmalem Breakdown of academic impact, for papers by Michelle Roytman Breakdown of academic impact, for papers by Steve Orme Breakdown of academic impact, for papers by Yi-Wen Chen Breakdown of academic impact, for papers by Anna Evangelista Breakdown of academic impact, for papers by M Houde
Rankless by CCL
2026